

Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030

Market Report | 2025-05-30 | 560 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The biomarkers market is expected to reach USD 104.15 billion in 2030 from USD 62.39 billion in 2025, at a CAGR of 10.8% during the forecast period. The growth of this market can be attributed to the advantage that these assay kits offer standardized and optimized protocols, facilitating accurate and efficient analysis of biomarkers in various biological samples, thus contributing significantly to diagnostic and research endeavors in healthcare. Further, advances in technologies such as genomics, proteomics, metabolomics, and next-generation sequencing have expanded the capabilities of biomarkers. This has led to the development of novel biomarkers with enhanced sensitivity, specificity, and predictive value.

"The predictive biomarkers segment accounted for the largest share of the efficacy biomarkers market in 2024."

The market by type is segmented into safety, efficacy, and validation biomarkers. Efficacy biomarkers are further segmented into predictive, surrogate, pharmacodynamic, and prognostic biomarkers. In 2024, the predictive biomarkers segment accounted for the largest share of the efficacy biomarkers segment in the global biomarkers market. This large share is supported by the ability of predictive biomarker-based offerings to guide treatment decisions and improve clinical outcomes by identifying patients most likely to benefit from a particular therapeutic intervention, which is especially valuable in oncology, autoimmune disorders, and infectious diseases. Moreover, the growing number of companion diagnostic approvals linked to predictive biomarkers further reinforced their adoption across healthcare settings. For instance, Roche's PATHWAY anti-HER2/neu (4B5) test identifies HER2-low breast cancer patients eligible for trastuzumab deruxtecan (ENHERTU), which received a label expansion in January 2025 to identify HER2-ultralow patients in HR-positive, HER2-negative metastatic breast cancer.

"Immunoassays held the largest share in the biomarker technologies market in 2024."

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. In 2024, immunoassays held the largest market share in the biomarkers market due to their high specificity and ability to detect various biomarkers across various disease areas, particularly in oncology, cardiology, and infectious diseases. Scalability and automation capabilities further support high-throughput testing, meeting the rising demand for precision diagnostics. Major companies are actively advancing immunoassay platforms to enhance their diagnostic offerings. For instance, Roche offers the Elecsys Anti-p53 immunoassay for cancer diagnostics, while Abbott continues to expand its ARCHITECT and Alinity immunoassay systems for infectious disease testing and chronic condition monitoring.

"The Asia Pacific region is growing at the highest CAGR in the biomarkers market during the forecast period."

The Asia Pacific is projected to register the highest growth rate in the biomarkers market during the forecast period. Key drivers of this growth include a large patient population undergoing advanced medical testing and supportive healthcare policies to improve cancer care. Additionally, increased research activity by pharmaceutical and biotechnology companies to develop novel drug therapies is expected to accelerate market expansion. As investment in drug development continues to rise across the region, the demand for biomarkers that support drug discovery and development efforts is growing steadily.

The primary interviews conducted for this report can be categorized as follows:

-□By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24%

-□By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25%

-□By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, Rest of the World- 15%

F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), and Laboratory Corporation of America Holdings (US) are some of the key players in the biomarkers market.

The study includes an in-depth competitive analysis of these key players in the biomarkers market, with their company profiles, recent developments, and key market strategies.

Research Coverage:

This research report categorizes the biomarkers market by offering [consumables (assay kits, columns & filters, reagents & chemicals), services, and software], type (safety biomarkers, efficacy biomarkers (surrogate biomarkers, pharmacodynamics biomarkers, predictive biomarkers, and prognostic biomarkers), and validation biomarkers), research area (genomics, proteomics, metabolomics, and other research area), technology [immunoassays (western blot, ELISA, and protein microarray), NGS, PCR, mass spectrometry, chromatography, and other technologies], disease indication (cancer, infectious diseases, cardiovascular disorders, immunological disorders, neurological disorders, and other disease indications), application (clinical diagnostics, drug discovery & development, personalized medicines, clinical research, and other applications), end user (pharmaceutical & biotechnologies companies, hospitals & diagnostics laboratories, research & academic institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report provides in-depth information on significant factors influencing the growth of the biomarkers market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches and acquisitions within the biomarkers market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the overall biomarkers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

-□Analysis of key drivers (increasing use of biomarkers in drug discovery & development, growing importance of companion diagnostics, rising prevalence of cancer, developments of biomarkers for rare diseases, increasing funds and grants for biomarker research, advancement in omics technologies), restraints (high capital investments and extensive timelines for biomarker

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

development, disease complexity, and heterogeneity), opportunities (growing preference for personalized medicine and precision oncology, enhanced collaboration among healthcare providers and key industry players, high growth potential of emerging economies), and challenges (issues associated with quantification and validation of biomarkers, complexities associated with data set integration, technical issues related to sample collection and storage) influencing the growth of the market.

- Product Development/Innovation: Detailed insights on newly launched products/services of the biomarkers market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the biomarkers market
- Competitive Assessment: In-depth assessment of market share, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMERIEUX (France), Agilent Technologies, Inc. (US), JSR Corporation (Japan), and Quanterix (US), among others, in the biomarkers market.

Table of Contents:

1□INTRODUCTION□	43
1.1□STUDY OBJECTIVES□	43
1.2□MARKET DEFINITION□	44
1.2.1□INCLUSIONS & EXCLUSIONS□	44
1.3□STUDY SCOPE□	46
1.3.1□STUDY SCOPE□	46
1.4□YEARS CONSIDERED□	47
1.5□CURRENCY CONSIDERED□	47
1.6□STAKEHOLDERS□	47
1.7□SUMMARY OF CHANGES□	48
2□RESEARCH METHODOLOGY□	49
2.1□RESEARCH DATA□	49
2.1.1□SECONDARY DATA□	50
2.1.2□PRIMARY DATA□	51
2.2□MARKET ESTIMATION METHODOLOGY□	52
2.2.1□INSIGHTS OF PRIMARY EXPERTS□	55
2.2.2□TOP-DOWN APPROACH□	55
2.3□MARKET GROWTH RATE FORECAST□	56
2.4□MARKET BREAKDOWN & DATA TRIANGULATION□	58
2.5□RESEARCH ASSUMPTIONS□	59
2.6□RESEARCH LIMITATIONS□	60
2.7□RISK ASSESSMENT□	61
3□EXECUTIVE SUMMARY□	62
4□PREMIUM INSIGHTS□	67
4.1□BIOMARKERS MARKET OVERVIEW□	67
4.2□ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING□	68
4.3□BIOMARKERS MARKET SHARE, BY END USER, 2024□	69
4.4□BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES□	69
5□MARKET OVERVIEW□	70
5.1□INTRODUCTION□	70
5.2□MARKET DYNAMICS□	70
5.2.1□MARKET DRIVERS□	72

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.2.1.1	Increasing use of biomarkers in drug discovery & development	72
5.2.1.2	Growing importance of companion diagnostics	72
5.2.1.3	Rising prevalence of cancer	73
5.2.1.4	Development of biomarkers for rare diseases	74
5.2.1.5	Increasing funds and grants for biomarker research	75
5.2.1.6	Advancement in omics technologies	76
5.2.2	RESTRAINTS	77
5.2.2.1	High capital investments and extensive timelines for biomarker development	77
5.2.2.2	Disease complexity and heterogeneity	78
5.2.3	OPPORTUNITIES	79
5.2.3.1	Growing preference for personalized medicine and precision oncology	79
5.2.3.2	Enhanced collaboration among healthcare providers and key industry players	79
5.2.3.3	High growth potential of emerging economies	80
5.2.4	CHALLENGES	81
5.2.4.1	Issues associated with quantification & validation of biomarkers	81
5.2.4.2	Complexities associated with data set integration	82
5.2.4.3	Technical issues related to sample collection and storage	82
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	82
5.4	REGULATORY ANALYSIS	83
5.4.1	REGULATORY SCENARIO	83
5.4.1.1	US	83
5.4.1.2	Europe	84
5.4.1.3	Asia Pacific	84
5.4.1.4	Rest of the World	85
5.4.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	85
5.5	VALUE CHAIN ANALYSIS	91
5.6	TECHNOLOGICAL ANALYSIS	93
5.6.1	KEY TECHNOLOGIES	93
5.6.1.1	Immunoassays	93
5.6.1.1.1	Immunohistochemistry (IHC)	93
5.6.1.1.2	ELISA	94
5.6.1.2	Next-generation Sequencing (NGS)	94
5.6.1.3	Polymerase chain reaction (PCR)	94
5.6.1.4	In situ hybridization	95
5.6.1.5	Microarrays	95
5.6.1.6	Mass Spectrometry	95
5.6.2	COMPLEMENTARY TECHNOLOGIES	96
5.6.2.1	Liquid biopsy	96
5.6.2.2	CRISPR	96
5.6.3	ADJACENT TECHNOLOGIES	96
5.6.3.1	Artificial intelligence (AI) and machine learning (ML)	96
5.6.3.2	Sensors (wearable devices)	96
5.7	PRICING ANALYSIS	97
5.7.1	INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2022-2024	97
5.7.2	INDICATIVE SELLING PRICE TREND OF BIOMARKER CONSUMABLES, BY REGION, 2024	98

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.8	PATENT ANALYSIS	99
5.8.1	METHODOLOGY	99
5.8.2	NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2025	99
5.9	ECOSYSTEM ANALYSIS	103
5.10	KEY CONFERENCES & EVENTS, 2025-2026	104
5.11	PORTER'S FIVE FORCES ANALYSIS	105
5.11.1	INTENSITY OF COMPETITIVE RIVALRY	106
5.11.2	BARGAINING POWER OF SUPPLIERS	106
5.11.3	BARGAINING POWER OF BUYERS	107
5.11.4	THREAT OF SUBSTITUTES	107
5.11.5	THREAT OF NEW ENTRANTS	107
5.12	KEY STAKEHOLDERS & BUYING CRITERIA	108
5.12.1	KEY STAKEHOLDERS IN BUYING PROCESS	108
5.12.2	BIOMARKERS MARKET: BUYING CRITERIA	109
5.13	INVESTMENT & FUNDING SCENARIO	110
5.14	TRADE DATA ANALYSIS	111
5.14.1	IMPORT SCENARIO: HS CODE 382200, 2020-2024	112
5.14.2	EXPORT SCENARIO: HS CODE 382200, 2020-2024	113
5.15	IMPACT OF AI/GENERATIVE AI ON BIOMARKERS MARKET	114
5.15.1	INTRODUCTION	114
5.15.2	USE CASES	114
5.15.3	FUTURE OF AI IN BIOMARKER ECOSYSTEM	116
5.16	IMPACT OF 2025 US TARIFF ON BIOMARKERS MARKET	116
5.16.1	KEY TARIFF RATES	117
5.16.2	PRICE IMPACT ANALYSIS	118
5.16.3	IMPACT ON COUNTRIES/REGIONS	119
5.16.3.1	US	119
5.16.3.2	Europe	120
5.16.3.3	Asia Pacific	121
5.16.4	IMPACT ON END-USE INDUSTRIES	121
5.16.4.1	Pharmaceutical & biotech companies	122
5.16.4.2	Hospitals & diagnostic laboratories	122
5.16.4.3	Contract research organizations	122
?		
6	BIOMARKERS MARKET, BY OFFERING	123
6.1	INTRODUCTION	124
6.2	CONSUMABLES	124
6.2.1	ASSAY KITS	128
6.2.1.1	Growing demand for assay kits in biomarker detection, quantification, and characterization to support growth	128
6.2.2	REAGENTS & CHEMICALS	132
6.2.2.1	Recurrent usage of reagents & chemicals in drug discovery and development to support demand	132
6.2.3	OTHER CONSUMABLES	136
6.3	SERVICES	139
6.3.1	GRADUAL TRANSITION FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING SERVICES TO FUEL MARKET EXPANSION	139
6.4	SOFTWARE	143
6.4.1	INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO DRIVE MARKET GROWTH	143
7	BIOMARKERS MARKET, BY TYPE	147

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.1	INTRODUCTION	148
7.2	SAFETY BIOMARKERS	148
7.2.1	WIDE APPLICATIONS OF SAFETY BIOMARKERS IN THERAPEUTIC AREAS TO BOOST MARKET GROWTH	148
7.3	EFFICACY BIOMARKERS	152
7.3.1	PREDICTIVE BIOMARKERS	155
7.3.1.1	Rising applications of biomarkers in personalized medicine to drive market	155
7.3.2	SURROGATE BIOMARKERS	159
7.3.2.1	Ability to serve as reliable indicator in place of clinical endpoints to support market growth	159
7.3.3	PHARMACODYNAMIC BIOMARKERS	163
7.3.3.1	Increasing utilization of pharmacodynamic biomarkers in biomarker and drug development to boost market	163
7.3.4	PROGNOSTIC BIOMARKERS	167
7.3.4.1	Increasing number of clinical trials to support growth of prognostic biomarkers	167
7.4	VALIDATION BIOMARKERS	170
7.4.1	RISING RESEARCH FOR NEW DRUG DISCOVERY & DEVELOPMENT TO BOOST MARKET GROWTH	170
8	BIOMARKERS MARKET, BY RESEARCH AREA	174
8.1	INTRODUCTION	175
8.2	GENOMICS	175
8.2.1	ADVANCEMENTS IN GENOMICS TECHNOLOGIES TO DRIVE SEGMENT GROWTH	175
8.3	PROTEOMICS	179
8.3.1	GROWING PATIENT POPULATION WITH CHRONIC DISEASES TO DRIVE DEMAND	179
8.4	METABOLOMICS	183
8.4.1	RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH	183
8.5	OTHER RESEARCH AREAS	186
9	BIOMARKERS MARKET, BY TECHNOLOGY	190
9.1	INTRODUCTION	191
9.2	IMMUNOASSAYS	191
9.2.1	ELISA	195
9.2.1.1	Extensive application of ELISA assays in clinical laboratories to support growth	195
9.2.2	PROTEIN MICROARRAYS	199
9.2.2.1	Quick and cost-effective nature of technology to support growth	199
9.2.3	WESTERN BLOT	203
9.2.3.1	Increasing investments in proteomics research to drive market	203
9.3	NEXT-GENERATION SEQUENCING (NGS)	206
9.3.1	TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO SUPPORT GROWTH	206
9.4	POLYMERASE CHAIN REACTION (PCR)	210
9.4.1	RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET	210
9.5	MASS SPECTROMETRY	214
9.5.1	INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE GROWTH	214
9.6	CHROMATOGRAPHY	217
9.6.1	GROWING UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH	217
9.7	OTHER TECHNOLOGIES	221
10	BIOMARKERS MARKET, BY DISEASE INDICATION	225
10.1	INTRODUCTION	226
10.2	CANCER	226
10.2.1	INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH AND DIAGNOSIS TO DRIVE MARKET	226
10.3	INFECTIOUS DISEASES	231

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.3.1	INCREASING RESEARCH AND GROWING FUNDING TO IDENTIFY BIOMARKERS FOR INFECTIOUS DISEASES TO DRIVE DEMAND	231
10.4	IMMUNOLOGICAL DISORDERS	235
10.4.1	RIISING ADOPTION OF ASSAYS FOR AUTOIMMUNE DISEASE DETECTION TO DRIVE MARKET	235
10.5	NEUROLOGICAL DISORDERS	239
10.5.1	WIDE USE OF BIOMARKERS IN DIAGNOSIS AND PRECISION MEDICINE OF NEUROLOGICAL DISORDERS TO SUPPORT GROWTH	239
10.6	CARDIOVASCULAR DISORDERS	243
10.6.1	GROWING PREVALENCE OF CVD TO INCREASE DEMAND FOR CARDIAC BIOMARKERS	243
10.7	OTHER DISEASE INDICATIONS	247
11	BIOMARKERS MARKET, BY APPLICATION	251
11.1	INTRODUCTION	252
11.2	CLINICAL DIAGNOSTICS	252
11.2.1	GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO SUPPORT DEMAND	252
11.3	DRUG DISCOVERY & DEVELOPMENT	256
11.3.1	INCREASING UTILIZATION OF BIOMARKERS IN DRUG DEVELOPMENT TO SUPPORT GROWTH	256
11.4	PERSONALIZED MEDICINE	260
11.4.1	GROWING PREFERENCE FOR PRECISION THERAPEUTICS TO SUPPORT DEMAND	260
11.5	CLINICAL RESEARCH	264
11.5.1	GROWING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET	264
11.6	OTHER APPLICATIONS	268
12	BIOMARKERS MARKET, BY END USER	272
12.1	INTRODUCTION	273
12.2	PHARMACEUTICAL & BIOTECHNOLOGIES COMPANIES	273
12.2.1	GROWING MARKET STRATEGIES BY KEY PLAYERS TO SUPPORT MARKET GROWTH	273
12.3	HOSPITALS & DIAGNOSTIC LABORATORIES	278
12.3.1	VITAL ROLE OF BIOMARKERS AS BIOLOGICAL INDICATORS IN DIAGNOSIS OF DISEASES TO FUEL MARKET GROWTH	278
12.4	ACADEMIC & RESEARCH INSTITUTES	282
12.4.1	INCREASING FUNDING ACTIVITIES TO DRIVE MARKET	282
12.5	OTHER END USERS	285
13	BIOMARKERS MARKET, BY REGION	289
13.1	INTRODUCTION	290
13.2	NORTH AMERICA	290
13.2.1	MACROECONOMIC OUTLOOK OF NORTH AMERICA	291
13.2.2	US	297
13.2.2.1	Rising focus on biopharma research to support growth	297
13.2.3	CANADA	302
13.2.3.1	Increasing incidence of cancer to drive biomarkers market growth	302
13.3	EUROPE	307
13.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	307
13.3.2	GERMANY	313
13.3.2.1	Growth in biopharmaceutical R&D activities to propel growth	313
13.3.3	UK	318
13.3.3.1	Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers	318
13.3.4	FRANCE	323
13.3.4.1	Increasing government investment for proteomics & genomics research to drive growth	323
13.3.5	ITALY	328

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.3.5.1	Increasing developments in life science research to fuel growth	328
13.3.6	SPAIN	332
13.3.6.1	R&D initiatives for personalized medicine to support market growth	332
13.3.7	REST OF EUROPE	337
13.4	ASIA PACIFIC	342
13.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	342
13.4.2	CHINA	349
13.4.2.1	Rising incidence of CVD to propel market	349
13.4.3	JAPAN	354
13.4.3.1	Strong regulatory guidelines for drug discovery & development to support market growth	354
13.4.4	INDIA	359
13.4.4.1	Favorable scenario for FDI and increasing number of clinical trials to propel market	359
13.4.5	SOUTH KOREA	364
13.4.5.1	Increasing innovations in NGS technologies to support market growth	364
13.4.6	AUSTRALIA	369
13.4.6.1	Increasing demand for diagnostic solutions to propel market	369
13.4.7	REST OF ASIA PACIFIC	373
13.5	LATIN AMERICA	378
13.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	378
13.5.2	BRAZIL	384
13.5.2.1	Increased government investments in pharmaceutical R&D to drive market	384
13.5.3	MEXICO	388
13.5.3.1	Rising demand for chronic disease treatment to support market growth	388
13.5.4	REST OF LATIN AMERICA	393
13.6	MIDDLE EAST	398
13.6.1	MACROECONOMIC OUTLOOK FOR MIDDLE EAST	398
13.6.2	GCC COUNTRIES	403
13.6.3	SAUDI ARABIA	407
13.6.3.1	Growing healthcare expenditure to boost market growth	407
13.6.4	UAE	412
13.6.4.1	Increasing collaborative efforts for pharmaceutical R&D to drive growth	412
	?	
13.6.5	REST OF GCC COUNTRIES	416
13.6.5.1	Other GCC countries include Bahrain, Kuwait, Oman, and Qatar.	416
13.6.6	REST OF MIDDLE EAST	421
13.6.6.1	The Rest of the Middle East includes Egypt, Turkey, Iran, and Iraq.	421
13.7	AFRICA	426
13.7.1	INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET	426
13.7.2	MACROECONOMIC OUTLOOK FOR AFRICA	426
14	COMPETITIVE LANDSCAPE	432
14.1	INTRODUCTION	432
14.2	KEY PLAYER STRATEGIES/RIGHT TO WIN	432
14.2.1	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET	432
14.3	REVENUE ANALYSIS, 2022-2024	436
14.4	MARKET SHARE ANALYSIS, 2024	438
14.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	441
14.5.1	STARS	442

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.5.2	EMERGING LEADERS	442
14.5.3	PERVASIVE PLAYERS	442
14.5.4	PARTICIPANTS	442
14.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	444
14.5.5.1	Company footprint	444
14.5.5.2	Region footprint	445
14.5.5.3	Offering footprint	446
14.5.5.4	Technology footprint	448
14.5.5.5	Application footprint	450
14.6	COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024	452
14.6.1	PROGRESSIVE COMPANIES	452
14.6.2	RESPONSIVE COMPANIES	452
14.6.3	DYNAMIC COMPANIES	452
14.6.4	STARTING BLOCKS	452
14.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	454
14.6.5.1	Detailed list of key startups/SMEs	454
14.6.5.2	Competitive benchmarking of key startups/SMEs	456
14.7	COMPANY VALUATION & FINANCIAL METRICS	457
14.7.1	VALUATION OF KEY PLAYERS	457
14.7.2	FINANCIAL METRICS OF KEY PLAYERS	457
14.8	BRAND/PRODUCT COMPARATIVE ANALYSIS	458
14.8.1	BIOMARKER MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF BIOMARKER-BASED ASSAYS	458
?		
14.9	COMPETITIVE SCENARIO	459
14.9.1	PRODUCT LAUNCHES & APPROVALS	459
14.9.2	DEALS	460
14.9.3	EXPANSIONS	461
15	COMPANY PROFILES	462
15.1	KEY PLAYERS	462
15.1.1	THERMO FISHER SCIENTIFIC INC.	462
15.1.1.1	Business overview	462
15.1.1.2	Products & services offered	463
15.1.1.3	Recent developments	469
15.1.1.3.1	Product launches & approvals	469
15.1.1.3.2	Deals	470
15.1.1.3.3	Expansions	471
15.1.1.4	MnM view	472
15.1.1.4.1	Right to win	472
15.1.1.4.2	Strategic choices	472
15.1.1.4.3	Weaknesses & competitive threats	472
15.1.2	MERCK KGAA	473
15.1.2.1	Business overview	473
15.1.2.2	Products & services offered	474
15.1.2.3	Recent developments	477
15.1.2.3.1	Deals	477
15.1.2.3.2	Expansions	478
15.1.2.4	MnM view	478

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1.2.4.1□Right to win□478
- 15.1.2.4.2□Strategic choices□478
- 15.1.2.4.3□Weaknesses & competitive threats□478
- 15.1.3□F. HOFFMANN-LA ROCHE LTD.□479
- 15.1.3.1□Business overview□479
- 15.1.3.2□Products & services offered□480
- 15.1.3.3□Recent developments□482
- 15.1.3.3.1□Product launches & approvals□482
- 15.1.3.3.2□Deals□485
- 15.1.4□QIAGEN□486
- 15.1.4.1□Business overview□486
- 15.1.4.2□Products & services offered□487
- 15.1.4.3□Recent developments□489
- 15.1.4.3.1□Product launches & approvals□489
- 15.1.4.3.2□Deals□490
- 15.1.4.3.3□Expansions□491
- ?
- 15.1.5□ABBOTT□492
- 15.1.5.1□Business overview□492
- 15.1.5.2□Products & services offered□493
- 15.1.5.3□Recent developments□495
- 15.1.5.3.1□Product launches & approvals□495
- 15.1.5.3.2□Deals□495
- 15.1.6□AGILENT TECHNOLOGIES, INC.□496
- 15.1.6.1□Business overview□496
- 15.1.6.2□Products & services offered□497
- 15.1.6.3□Recent developments□498
- 15.1.6.3.1□Product launches & approvals□498
- 15.1.6.3.2□Deals□499
- 15.1.7□REVVITY INC.□501
- 15.1.7.1□Business overview□501
- 15.1.7.2□Products & services offered□502
- 15.1.8□CHARLES RIVER LABORATORIES□504
- 15.1.8.1□Business overview□504
- 15.1.8.2□Products & services offered□505
- 15.1.8.3□Recent developments□506
- 15.1.8.3.1□Deals□506
- 15.1.9□BIO-RAD LABORATORIES, INC.□507
- 15.1.9.1□Business overview□507
- 15.1.9.2□Products & services offered□508
- 15.1.9.3□Recent developments□510
- 15.1.9.3.1□Product launches□510
- 15.1.9.3.2□Deals□510
- 15.1.10□EUROFINS SCIENTIFIC□511
- 15.1.10.1□Business overview□511
- 15.1.10.2□Products & services offered□512
- 15.1.10.3□Recent developments□513

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1.10.3.1 Deals 513
- 15.1.11 BIOMERIEUX 514
 - 15.1.11.1 Business overview 514
 - 15.1.11.2 Products & services offered 515
 - 15.1.11.3 Recent developments 516
 - 15.1.11.3.1 Product launches & approvals 516
 - 15.1.11.3.2 Deals 516
- 15.1.12 ILLUMINA, INC. 517
 - 15.1.12.1 Business overview 517
 - 15.1.12.2 Products & services offered 519
 - 15.1.12.3 Recent developments 519
 - 15.1.12.3.1 Product launches & approvals 519
 - 15.1.12.3.2 Deals 520
- 15.1.13 SR CORPORATION 521
 - 15.1.13.1 Business overview 521
 - 15.1.13.2 Products & services offered 522
 - 15.1.13.3 Recent developments 523
 - 15.1.13.3.1 Deals 523
- 15.1.14 GUARDANT HEALTH 524
 - 15.1.14.1 Business overview 524
 - 15.1.14.2 Products & services offered 526
 - 15.1.14.3 Recent developments 526
 - 15.1.14.3.1 Product launches & approvals 526
 - 15.1.14.3.2 Deals 527
- 15.1.15 LABCORP 529
 - 15.1.15.1 Business overview 529
 - 15.1.15.2 Products & services offered 530
 - 15.1.15.3 Recent developments 531
 - 15.1.15.3.1 Product launches 531
- 15.1.16 QUANTERIX 532
 - 15.1.16.1 Business overview 532
 - 15.1.16.2 Products & services offered 533
 - 15.1.16.3 Recent developments 534
 - 15.1.16.3.1 Product launches 534
 - 15.1.16.3.2 Deals 534
- 15.1.17 MESO SCALE DIAGNOSTICS, LLC 535
 - 15.1.17.1 Business overview 535
 - 15.1.17.2 Products & services offered 535
- 15.2 OTHER PLAYERS 537
 - 15.2.1 CELERION 537
 - 15.2.2 STANDARD BIOTOOLS 538
 - 15.2.3 SEBIA 539
 - 15.2.4 BIOAGILITY LABS 540
 - 15.2.5 STRESSMARQ BIOSCIENCES INC. 541
 - 15.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC 542
 - 15.2.7 SIGNOSIS 543
 - 15.2.8 SERIMMUNE 544

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.2.9 THERAINDX LIFESCIENCES PVT. LTD. 544

15.2.10 SYNEXA LIFE SCIENCES BV 545

15.2.11 DIATECH PHARMACOGENETICS 546

15.2.12 SINGULEX, INC. 547

15.2.13 R-BIOPHARM AG 548

?

16 APPENDIX 549

16.1 DISCUSSION GUIDE 549

16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 555

16.3 CUSTOMIZATION OPTIONS 557

16.4 RELATED REPORTS 558

16.5 AUTHOR DETAILS 559

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030

Market Report | 2025-05-30 | 560 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-06-14
		Signature	<div></div>